Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

28.89 +0.28 (+0.98%)
Streaming Delayed Price Updated: 10:04 AM EDT, Jun 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
News headline image
Is Viking Therapeutics Stock Going to $100? ↗
Viking stock is known for soaring after positive news. 
Via The Motley Fool
News headline image
Why 1 Wall Street Analyst Thinks Viking Therapeutics Stock Could Soar 188% ↗
If you look beyond the upside potential, there's still plenty of risk to navigate past. 
Via The Motley Fool
News headline image
1 Sector Warren Buffett and Greg Abel Are Largely Ignoring -- and Why Investors Shouldn't ↗
This particular sector may suit cautious and aggressive investors. 
Via The Motley Fool
Viking Therapeutics (NASDAQ:VKTX) Stock Holds Steady After Q1 2026 Earnings Miss on Higher Phase 3 Spending ↗
Via Chartmill
Topics Earnings
News headline image
Bull vs. Bear: The Quick Take on Viking Therapeutics Stock ↗
The pharmaceutical company's most promising drug candidate has some potential advantages over its rivals. 
Via The Motley Fool
News headline image
Viking Therapeutics' Q3 Catalyst That Could Turn Eli Lilly's and Novo Nordisk's Daily Weight Loss Pill Strategy Upside Down ↗
An upcoming trial result could change how investors think about the weight-loss drug market. 
Via The Motley Fool
News headline image
The Smartest Growth Stocks to Buy With $2,000 Right Now ↗
Most of the market's best-known growth names are overbought at this time. That's not the case for several off-the-radar alternatives. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Prediction: These 2 Obesity Drug Stocks Could Double in 2026 ↗
These players are seeing exciting results in clinical trials. 
Via The Motley Fool
News headline image
Don't Buy Viking Therapeutics Stock Until You Read This ↗
It may be too late for Viking to take on the "dark horse" role in the GLP-1 wars. 
Via The Motley Fool
News headline image
Eli Lilly Just Made a Game-Changing Move in the Billion-Dollar Weight Loss Drug Space. Here's What You Need to Know. ↗
The pharma giant is taking steps to expand its portfolio. 
Via The Motley Fool
News headline image
Is Viking Therapeutics a Top Takeover Target? ↗
Viking's strong obesity drug data continues fueling acquisition speculation. 
Via The Motley Fool
News headline image
2 Stocks That Could Realistically Double by 2030 ↗
Long-time shareholders are already pretty satisfied with these companies, but there might be even more upside ahead. 
Via The Motley Fool
News headline image
Could Viking Therapeutics Be the Next Eli Lilly? ↗
Demand for weight loss drugs may fuel growth for more than one player. 
Via The Motley Fool
News headline image
Best Weight Loss Drug Stocks to Buy in 2026 ↗
If you are looking for a GLP-1 investment, you can buy the leader, the underdog, or the upstart. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics' Pill Could Crash the Weight-Loss Party ↗
This dark horse in the weight loss drug race is worth keeping on your watch list. 
Via The Motley Fool
News headline image
Eli Lilly Stock: Next Stop $2,000? ↗
The company is riding an incredible tailwind. 
Via The Motley Fool
News headline image
Should Eli Lilly Investors Worry About Its Newest Rival -- From Within? ↗
Eli Lilly is dominating one of the biggest growth markets in healthcare: the weight loss drug market. 
Via The Motley Fool
Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
Via Investor Brand Network
InvestorNewsBreaks – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Featured in BioMedWire Editorial on Next-Generation GLP-1 Innovation
Via Investor Brand Network
News headline image
Here's Exactly Why Wall Street Thinks Viking Therapeutics Stock Could Soar 207% Over the Next 12 Months ↗
The Street is bullish on this biotech's prospects, but is the sentiment justified? 
Via The Motley Fool
News headline image
Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
From BioMedWire
Via GlobeNewswire
News headline image
Eli Lilly Just Announced Fantastic News for Shareholders ↗
Lilly's weight loss drugs have been delivering blockbuster revenue. 
Via The Motley Fool
Topics Earnings
News headline image
Viking Therapeutics Faces Timeline Risk—But Upside Could Be Huge ↗
Via MarketBeat
News headline image
Should You Forget This High-Yield Pharma Stock and Buy a Growth Name Instead? ↗
This particular player has seen its yield rise in recent years. 
Via The Motley Fool
News headline image
This Obesity Stock Could More Than Double Over the Next 12 Months, According to Wall Street ↗
Most investors currently see the glass on this stock as being half-empty. Analysts, however, still view the glass as at least half-full. 
Via The Motley Fool
News headline image
Is This Tech Giant the Next Potential Winner in the GLP-1 Weight Loss Boom? ↗
The weight loss drug market may reach almost $100 billion in a few years. 
Via The Motley Fool
News headline image
The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
From stem cell therapies for frailty to α-Klotho protein programs and GLP-1 drug classes now labeled "longevity therapeutics," the science and the capital have finally met 
From Equity Insider
Via GlobeNewswire
News headline image
Better Long-Term Buy: Eli Lilly or Viking Therapeutics? ↗
One is a behemoth, the other is a minnow, but both have promising opportunities in the GLP-1 space. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Is Viking Therapeutics the Ultimate Millionaire-Maker Obesity Stock for 2026? ↗
The stock could have plenty of room to run from current levels. 
Via The Motley Fool
News headline image
Better Healthcare Stock to Own in a Recession: Defensive or Growth? ↗
The answer to the question might surprise many investors. It pays to be open-minded about risk. 
Via The Motley Fool
Topics Economy Energy
< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.